Longer Colonoscopy Withdrawal Time May Cut Cancer Risk

This article originally appeared here.
Share this content:
Longer Colonoscopy Withdrawal Time May Cut Cancer Risk
Longer Colonoscopy Withdrawal Time May Cut Cancer Risk

THURSDAY, Aug. 27, 2015 (HealthDay News) -- Longer colonoscopy withdrawal time is associated with lower risk for colorectal cancer over five years, according to a study published online recently in Gastroenterology.

Researchers reviewed 76,810 screening colonoscopies performed over six years by 51 gastroenterologists at a large practice in Minnesota. On average, colonoscopy withdrawal times lasted nearly nine minutes, but about 10 percent of the doctors had individual averages of less than six minutes, the investigators found.

Patients whose screenings were performed by doctors whose average colonoscopy withdrawal time lasted less than six minutes were twice as likely to develop colorectal cancer within five years as those whose doctors' colonoscopy withdrawal time averaged more than six minutes, the researchers found. Colonoscopy withdrawal times that went beyond eight minutes did not seem to provide an extra reduction in cancer risk.

"Our results support the use of withdrawal time as a quality indicator, as recommended by current guidelines," lead author Aasma Shaukat, M.D., M.P.H., of the Minneapolis Veterans Affairs Health Care System, said in a VA news release.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths